Vir Biotechnology, Inc.(VIR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,846 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
VIR Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Vir Biotechnology, Inc. (VIR), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VIR at 5.6/100 on a 32-signal composite quality model, placing it at rank #2,846 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (0.2) and free cash flow (0.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 3.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Vir Biotechnology, Inc. reports quarterly revenue of $-29.0K, net income of $-125.7M, free cash flow of $-132.8M. Top institutional holders of VIR by reported 13-F value include BlackRock,, ARCH Venture Management,, SB INVESTMENT ADVISERS (UK) LTD, based on the most recent SEC filings. VIR trades on the Nasdaq exchange and files with the SEC under CIK 1706431. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VIR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Vir Biotechnology, Inc. directly from SEC EDGAR. Vir Biotechnology, Inc.'s 13F Pro composite quality score has ranged between 4 and 84 since 2021, currently 5.6 — a declining long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q1 2026
$-29.0K
Net Income
Q1 2026
$-125.7M
Free Cash Flow
Q1 2026
$-132.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-7.6% YoYNet Income
+16.1% YoYOperating Income
+18.4% YoYEPS (Diluted)
+17.5% YoYTotal Assets
-28.3% YoYOp. Cash Flow
+12.2% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $68.6M -7.6% | $74.2M -13.9% | $86.2M +12.8% | $76.4M +843.9% | $8.1M -24.2% | $10.7M |
| Net Income | $-438.0M +16.1% | $-522.0M +15.1% | $-615.1M -105.9% | $-298.7M -71.0% | $-174.7M -50.7% | $-115.9M |
| Operating Income | $-479.3M +18.4% | $-587.2M +14.2% | $-684.3M -130.4% | $-297.0M -66.9% | $-178.0M -50.0% | $-118.7M |
| EPS (Diluted) | $-3.16 +17.5% | $-3.83 +16.6% | $-4.59 -82.9% | $-2.51 +56.4% | $-5.76 | — |
| Total Assets | $1.00B -28.3% | $1.40B -27.1% | $1.92B +108.9% | $918.8M +79.4% | $512.1M +167.3% | $191.6M |
| Operating Cash Flow | $-391.8M +12.2% | $-446.4M +42.7% | $-778.8M -307.9% | $-190.9M -47.3% | $-129.6M -37.8% | $-94.1M |
AI Insight: VIR Financial Trends
Vir Bio burns through equity relentlessly — a brief Q4 2025 revenue spike to $64M reversed sharply to near-zero in Q1 2026, leaving losses at $126M.
• Revenue collapsed from $64M in Q4 2025 back to effectively $0M in Q1 2026, indicating Q4 was a one-time event, not a recovery.
• Operating losses have ranged from $48M to $231M per quarter across the eight periods, with no sustained improvement trend.
• Equity eroded from $1,044M in Q1 2025 to $796M in Q3 2025, partially recovering to $813M in Q1 2026 — still down ~22% over four quarters.
• Operating cash outflow reached $168M in Q3 2025 and $132M in Q1 2026, reflecting persistently heavy cash consumption.
⚠ The source of Q4 2025's $64M revenue spike is critical — if non-recurring, the underlying business generates near-zero revenue.
⚠ Equity declining from $1,044M toward $813M over five quarters signals runway erosion; debt data absent, making solvency hard to assess.
⚠ Operating cash burn of $132M in Q1 2026 matches the worst quarters — any further acceleration raises near-term financing risk.
AI Insight: VIR Ratio Trends
Vir Biotechnology remains deeply unprofitable with ROA worsening to -49.0% in Q1 2026 and no operating margin data available for most periods.
• ROA deteriorated sharply in Q3 2025 to -64.0% from -37.2% in Q2 2025, then partially recovered to -49.0% in Q1 2026.
• ROE swung from -46.4% in Q1 2025 to -82.0% in Q3 2025, indicating accelerating equity erosion mid-year.
• ROIC worsened from -53.5% in Q1 2025 to -87.2% in Q3 2025, with Q2 2025 showing a modest sequential improvement to -50.0%.
⚠ Q4 2025 operating margin of -74.8% is the only available OpMargin data point — insufficient to assess directional trend.
⚠ TTM ROA of -43.2% and ROIC of -58.1% signal sustained capital destruction; no leverage data available to assess debt risk.
Get alerted when VIR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Vir Biotechnology, Inc. including:
Top Institutional Holders of VIR
BlackRock, Inc.
$161.3M17,998,329 shARCH Venture Management, LLC
$115.7M12,916,663 shSB INVESTMENT ADVISERS (UK) LTD
$98.1M10,948,093 shVANGUARD PORTFOLIO MANAGEMENT LLC
$82.6M9,215,577 shGSK plc
$76.6M8,550,954 shSTATE STREET CORP
$64.0M7,141,094 shVANGUARD CAPITAL MANAGEMENT LLC
$48.2M5,382,103 shGOLDMAN SACHS GROUP INC
$29.1M3,250,227 shMORGAN STANLEY
$25.6M2,854,205 shADAR1 Capital Management, LLC
$24.6M2,744,714 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $161.3M | 17,998,329 |
| ARCH Venture Management, LLC | $115.7M | 12,916,663 |
| SB INVESTMENT ADVISERS (UK) LTD | $98.1M | 10,948,093 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $82.6M | 9,215,577 |
| GSK plc | $76.6M | 8,550,954 |
| STATE STREET CORP | $64.0M | 7,141,094 |
| VANGUARD CAPITAL MANAGEMENT LLC | $48.2M | 5,382,103 |
| GOLDMAN SACHS GROUP INC | $29.1M | 3,250,227 |
| MORGAN STANLEY | $25.6M | 2,854,205 |
| ADAR1 Capital Management, LLC | $24.6M | 2,744,714 |
More Healthcare Companies
View all Healthcare →Put VIR on your watchlist
Track score changes the day Vir Biotechnology, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VIR a good stock to buy?
13F Pro's AI-powered analysis of Vir Biotechnology, Inc. (VIR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VIR are available on the VIR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own VIR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VIR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Vir Biotechnology, Inc.'s investment landscape.